Q1 FY 2027 saw 13.7% year-on-year revenue growth, strong pharma and export performance, and stable margins despite global headwinds. Biologics operations began with first client onboarded, and CapEx remains disciplined with a net debt-free balance sheet.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.